Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 119

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer

Jiang, Zehang, Liu, Zhixian, Li, Mengyuan, Chen, Cai, Wang, Xiaosheng · 2018 · Translational Oncology

Abstract

Although immunotherapy continues to demonstrate efficacy in a variety of refractory cancers, currently, no any immunotherapeutic strategy is clinically used for gastric cancer (GC) except its microsatellite instable subtype. Thus, it is important to identify molecular biomarkers for predicting the responders to GC immunotherapy. TP53 mutations frequently occur in GC and are associated with unfavorable clinical outcomes in GC. We performed a comprehensive characterization of the associations between TP53 mutations and immune activities in GC based on two large-scale GC cancer genomics data. We compared expression and enrichment levels of 787 immune-related genes and 23 immune gene-sets among TP53-mutated GCs, TP53-wildtype GCs, and normal tissue, and explored the correlations between p53-mediated pathways and immune activities in GC. Strikingly, almost all analyzed immune gene-sets were significantly downregulated in enrichment levels in TP53-mutated GCs compared to TP53-wildtype GCs. These less active immune pathways and cell types in TP53-mutated GCs included 15 immune cell types and function, tumor-infiltrating lymphocytes, regulatory T cells, immune checkpoint, cytokine and cytokine receptor, human leukocyte antigen, pro-inflammatory, and parainflammation. Moreover, we identified a number of p53-mediated pathways and proteins that were significantly associated with immune activities in GC. Furthermore, we demonstrated that the TP53 mutation itself could result in the depressed immune activities in GC and other cancer types. We revealed that chromosomal instability was an important mechanism for the depressed tumor immunity in TP53-mutated cancers. Finally, we showed that immune cell infiltration and immune activities were likely positively associated with survival prognosis in GC. Our findings suggest that p53 may play an important role in activating tumor immunity in GC and other cancer types and that the TP53 mutation status could be useful in stratifying cancer patients responsive to a certain immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tranon.2018.07.012

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 34

  1. Wang, 2017, TP53 mutations, expression and interaction networks in human cancers, Oncotarget, 8, 624, 10.18632/oncotarget.13483 · DOI
  2. Munoz-Fontela, 2016, Emerging roles of p53 and other tumour-suppressor genes in immune regulation, Nat Rev Immunol, 16, 741, 10.1038/nri.2016.99 · DOI · Paper page
  3. Zitvogel, 2015, CANCER. A p53-regulated immune checkpoint relevant to cancer, Science, 349, 476, 10.1126/science.aac8475 · DOI
  4. Shatz, 2012, The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells, Cancer Res, 72, 3948, 10.1158/0008-5472.CAN-11-4134 · DOI · Paper page
  5. Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer cell, 27, 450, 10.1016/j.ccell.2015.03.001 · DOI · Paper page
  6. Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498 · DOI · Paper page
  7. Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 · DOI · Paper page
  8. Taube, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res, 20, 5064, 10.1158/1078-0432.CCR-13-3271 · DOI · Paper page
  9. Le, 2015, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 · DOI · Paper page
  10. Ye, 2016, Genomic alterations and molecular subtypes of gastric cancers in Asians, Chin J Cancer, 35, 42, 10.1186/s40880-016-0106-2 · DOI
  11. Chen, 2015, The updated incidences and mortalities of major cancers in China, 2011, Chin J Cancer, 34, 502
  12. Cristescu, 2015, Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes, Nat Med, 21, 449, 10.1038/nm.3850 · DOI · Paper page
  13. Chen, 2016, Emerging molecular classifications and therapeutic implications for gastric cancer, Chin J Cancer, 35, 49, 10.1186/s40880-016-0111-5 · DOI
  14. Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 · DOI · Paper page
  15. Benjami, 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J R Stat Soc B, 57, 289, 10.1111/j.2517-6161.1995.tb02031.x · DOI · Paper page
  16. Kim, 2015, ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients, Commun Stat Appl Methods, 22, 665
  17. Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967 · DOI · Paper page
  18. Lee, 2015, Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes, Breast Cancer Res Treat, 151, 619, 10.1007/s10549-015-3438-8 · DOI
  19. Massink, 2015, Genomic profiling of CHEK2*1100delC-mutated breast carcinomas, BMC Cancer, 15, 877, 10.1186/s12885-015-1880-y · DOI
  20. De Simone, 2016, Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells, Immunity, 45, 1135, 10.1016/j.immuni.2016.10.021 · DOI · Paper page
  21. Lippitz, 2013, Cytokine patterns in patients with cancer: a systematic review, Lancet Oncol, 14, e218, 10.1016/S1470-2045(12)70582-X · DOI · Paper page
  22. Wong, 2016, Characterization of cytokinome landscape for clinical responses in human cancers, Oncoimmunology, 5, 10.1080/2162402X.2016.1214789 · DOI
  23. Caballero, 2009, Cancer/testis (CT) antigens: potential targets for immunotherapy, Cancer Sci, 100, 2014, 10.1111/j.1349-7006.2009.01303.x · DOI · Paper page
  24. Almeida, 2009, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Res, 37, D816, 10.1093/nar/gkn673 · DOI · Paper page
  25. Renaud, 2007, Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors, Nucleic Acids Res, 35, 7372, 10.1093/nar/gkm896 · DOI
  26. Munro, 1976, Products of the major histocompatibility complex and their relationship to the immune response, Nature, 264, 145, 10.1038/264145a0 · doi:10.1038/264145a0
  27. Wang, 2013, p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1, Nat Commun, 4, 2359, 10.1038/ncomms3359 · DOI
  28. Fritsch, 2014, Personal neoantigen cancer vaccines: The momentum builds, Oncoimmunology, 3, 10.4161/onci.29311 · DOI
  29. Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025 · DOI · Paper page
  30. Bedognetti, 2015, Prognostic and predictive immune gene signatures in breast cancer, Curr Opin Oncol, 27, 433, 10.1097/CCO.0000000000000234 · DOI
  31. Aran, 2016, Widespread parainflammation in human cancer, Genome Biol, 17, 145, 10.1186/s13059-016-0995-z · DOI
  32. Kastenhuber, 2017, Putting p53 in Context, Cell, 170, 1062, 10.1016/j.cell.2017.08.028 · DOI · Paper page
  33. Wang, 2017, TP53 mutations, expression and interaction networks in human cancers, Oncotarget, 8, 624, 10.18632/oncotarget.13483 · DOI
  34. Kawamura, 2004, Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression, Cancer Res, 64, 4800, 10.1158/0008-5472.CAN-03-3908 · DOI

Cited by

Metadata

Authors
Jiang, Z., Liu, Z., Li, M., Chen, C., & Wang, X.
Venue
Translational Oncology
Publisher
Elsevier BV
Published
2018-10
Volume
11
Issue
5
Pages
1171-1187
ISSN
1936-5233
Cited by
119
References
18
Language
en
Licence
Funders
China Pharmaceutical University (3150120001, 2632018YX01)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.